UHealth - University of Miami Health System

Nicolas Acquavella Pesantes, M.D.

Información general

Nicolas  Acquavella Pesantes, M.D.



  • English
  • Italian
  • Spanish


  • American Board of Internal Med-Medical Oncology
  • American Board of Internal Medicine



  • Hematology/Oncology - Internal Medicine
  • Internal Medicine


  • Assistant Professor of Clinical Medicine
  • Member, Immunotherapy Program
  • Member, Phase I Clinical Trials Program

Intereses clínicas

Clinical Expertise: Melanoma and Pancreatic Cancer; Immunotherapy and Targeted Therapy

Intereses de

Melanoma Clinical Trials:
1. A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAF V600 Mutant Melanoma.
2. A Phase III Randomized trial comparing High Dose Interferon to MK-3475 (Pembrolizumab) in patients with high risk resected Melanoma.
3. Phase 1b Trial of AEB071, a PKC Inhibitor, in Combination with BYL719, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma.
4. A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for the Treatment of Unresectable Stage IIIB to IVM1c Melanoma.
Pancreatic Cancer Clinical Trials:
1. A Multicenter Randomized Phase II study of the monoclonal antibody NPC-1C in combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in patients with Metastatic or Locally Advanced Pancreatic Cancer previously treated with FOLFIRINOX.
2. A Randomized Multicenter Phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with MK- 3475 (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.
3. A Phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma. Accrual completed.
4. A Phase III study of chemotherapy with or without Algenpantucel-L ) HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Accrual completed.
5. A randomized multicenter Phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable or borderline resectable cancer. Accrual completed.


MD, Universidad Central de Venezuela

Residency, Yale New Haven Hospitals

Fellowship, National Cancer Institute / National Institutes of Health



Nicolas Acquavella, M.D., is a board-certified medical oncologist dedicated to providing innovative and advanced treatment options to patients with metastatic melanoma and pancreatic cancer. Dr. Acquavella’s research focuses on mobilizing the body’s immune system to seek out and destroy cancer cells. In close collaboration with a multidisciplinary group of scientists, pharmaceutical companies and clinicians Dr. Acquavella works to move the most promising cancer therapies from the laboratory into the clinic. In collaboration with his colleagues at the Bascom Palmer Eye Institute at the University of Miami – the No. 1 eye hospital in the nation – Dr. Acquavella is committed to develop novel therapies for uveal melanoma, a rare type of melanoma that occurs in the eye and for which no effective therapies exist. His current research involves combining immune-based therapies with viruses genetically modified to destroy cancer cells.

E-mail a Friend